Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
555 patients with Child-Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
IrAEs occurred in 13.3% (grade 5: 0.7%). [CONCLUSIONS] uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.
[BACKGROUND] Findings regarding long-term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported.
APA
Ohama H, Hiraoka A, et al. (2026). Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.. Cancer medicine, 15(2), e71640. https://doi.org/10.1002/cam4.71640
MLA
Ohama H, et al.. "Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.." Cancer medicine, vol. 15, no. 2, 2026, pp. e71640.
PMID
41692425 ↗
Abstract 한글 요약
[BACKGROUND] Findings regarding long-term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real-world clinical settings.
[METHODS] This multicenter retrospective study included 555 patients with Child-Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression-free survival (PFS), overall survival (OS), post-progression survival (PPS), and immune-related adverse events (irAEs) were analyzed.
[RESULTS] Median age was 73 years and 80.2% were male. Atez/Bev was given as first-line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first-line therapy showed a higher 3 year survival rate of 35.9%. Post-progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%).
[CONCLUSIONS] uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.
[METHODS] This multicenter retrospective study included 555 patients with Child-Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression-free survival (PFS), overall survival (OS), post-progression survival (PPS), and immune-related adverse events (irAEs) were analyzed.
[RESULTS] Median age was 73 years and 80.2% were male. Atez/Bev was given as first-line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first-line therapy showed a higher 3 year survival rate of 35.9%. Post-progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%).
[CONCLUSIONS] uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Bevacizumab
- Female
- Liver Neoplasms
- Aged
- Carcinoma
- Hepatocellular
- Retrospective Studies
- Antibodies
- Monoclonal
- Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Middle Aged
- 80 and over
- Treatment Outcome
- Progression-Free Survival
- IMbrave150 trial
- atezolizumab plus bevacizumab
- durvalumab plus tremelimumab
- hepatocellular carcinoma
- prognosis
같은 제1저자의 인용 많은 논문 (3)
- Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.
- Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma.
- Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.